Bio-Rad (BIO) Q3 2025: Process Chromatography Delivers Double-Digit Growth, Offsetting U.S. Research Weakness
Process chromatography strength and disciplined cost management offset persistent academic research headwinds, keeping Bio-Rad on track for full-year targets. Demand for new Droplet Digital PCR systems is building but sales cycles remain long, while China’s diagnostics headwinds are expected to annualize in Q4. Margin expansion signals are emerging for 2026, but macro and funding uncertainties persist, especially in U.S. research and China.
Summary
- Process Chromatography Volatility: Order timing drove double-digit growth, but normalization is expected next year.
- Funding Caution in U.S. Research: Academic and biotech softness continues to weigh on core life science revenue.
- Margin Expansion Focus: Operational discipline and supply chain initiatives set the stage for 2026 improvement.
Business Overview
Bio-Rad Laboratories is a global provider of life science research tools and clinical diagnostics platforms, generating revenue through the sale of instruments, consumables, and reagents. Its two major segments are Life Science (supporting research and bioproduction with technologies like process chromatography and digital PCR) and Clinical Diagnostics (enabling disease testing and monitoring, particularly in diabetes and quality controls). The company’s business model relies on recurring consumables and instrument placements, with segment performance influenced by research funding cycles and healthcare reimbursement trends.
Performance Analysis
Bio-Rad posted modest top-line growth with revenue flat to slightly up year-over-year on a reported basis, but currency-neutral sales declined in both major segments. The Life Science segment was essentially flat, with process chromatography, purification of biomolecules in biomanufacturing, delivering double-digit growth due to customer order timing. However, core life science revenue (excluding process chromatography) fell 6% YoY, reflecting ongoing softness in academic research and biotech funding, particularly in the Americas, where academic institutions tightened budgets and delayed purchases.
Clinical Diagnostics revenue was stable overall, with growth in the Americas and EMEA offsetting a decline in Asia-Pacific, primarily due to lower diabetes test reimbursement rates in China. Gross margin contracted year-over-year, pressured by higher material costs and lower manufacturing absorption, but strong cost controls and lower R&D spending helped deliver a sequential improvement in operating margin. Free cash flow remained robust, and the company continued to execute on its share buyback program.
- Process Chromatography Timing: Q3 benefited from order pull-forward, but Q4 and 2026 are expected to normalize to high single-digit growth.
- Droplet Digital PCR (DDPCR) Pipeline: New QX platform launches generated strong customer interest, but extended sales cycles and cautious research budgets are tempering near-term revenue.
- China Diagnostics Headwind: Lower diabetes reimbursement rates continued to impact Asia-Pacific sales, but the effect will annualize in Q4, setting up for a more stable 2026.
Cost discipline and operational agility allowed Bio-Rad to maintain guidance despite persistent external pressures, with management emphasizing the balance between near-term execution and long-term innovation investment.
Executive Commentary
"Our clinical diagnostic segment remains stable across our product areas, aside from the reimbursement rate headwind in China, which we expect to analyze in the fourth quarter. In our life science segment, process chromatography delivered a strong performance, helping offset the continued softness we're seeing in academic research and biotech funding."
John DiVincenzo, President and Chief Operating Officer
"We are maintaining our 2025 full year outlook with total currency neutral revenue growth being the range of flat to 1%, our full year 2025 non-GAAP gross and operating margin outlook also remains unchanged at 53.5% to 54.5% and 12% to 13% respectively."
Rupalak Raju, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Process Chromatography: Short-Term Surge, Normalization Ahead
Process chromatography delivered double-digit growth in Q3, driven by the timing of large customer orders. Management signaled this was not sustainable, with guidance for a sequential and year-over-year decline in Q4 and a return to high single-digit growth in 2026. Volatility in this business reflects the lumpiness of biomanufacturing investment cycles.
2. Droplet Digital PCR (DDPCR): Platform Expansion and Pipeline Momentum
Bio-Rad advanced its DDPCR strategy with the global rollout of new QX platforms and expanded partnerships for oncology and biomarker testing. Customer receptivity is strong, especially for entry-level systems, but sales cycles are extended due to cautious research funding. The company expects a rebound in instrument placements and consumables as funding visibility improves.
3. Clinical Diagnostics: Navigating China Reimbursement and Quality Controls
China’s diabetes testing reimbursement cuts weighed on results, but the impact will soon annualize. The company’s quality controls portfolio remains a relative strength in China and is expected to drive Q4 growth. Management does not anticipate new reimbursement headwinds in 2026 but remains cautious on the macro outlook for the region.
4. Operational Discipline: Margin and Productivity Focus
Disciplined cost management, lean manufacturing initiatives, and supply chain optimization drove margin outperformance in Q3. Management highlighted further opportunities for productivity gains and buying leverage in 2026, aiming for sequential margin expansion even in a low-growth environment.
Key Considerations
Bio-Rad’s Q3 performance highlights the company’s ability to navigate a challenging funding and macro environment while positioning for longer-term growth and margin improvement. Investors should monitor these key factors:
- Academic and Biotech Funding Sensitivity: Core life science revenue remains exposed to U.S. research budget delays and weak biotech funding, with recovery contingent on NIH appropriations and sentiment shifts.
- Process Chromatography Volatility: Order timing drove Q3 strength, but normalization and less favorable comparisons are expected in Q4 and 2026.
- China Diagnostics Exposure: The reimbursement headwind will annualize, but broader macro softness in China could dampen diagnostics demand next year.
- Margin Expansion Levers: Lean initiatives, supply chain optimization, and OpEx discipline are central to the 2026 outlook, especially if top-line growth remains modest.
Risks
Persistent funding uncertainty in U.S. academic research and biotech could further delay core life science recovery, while China’s macro environment and potential regulatory changes remain unpredictable. Gross margin remains vulnerable to inflation and supply chain disruptions. Extended sales cycles for new platforms and reliance on order timing in process chromatography add to earnings volatility. Management’s cautious tone on U.S. research and China signals ongoing risk to both revenue and margin expansion efforts.
Forward Outlook
For Q4 2025, Bio-Rad expects:
- Modest sequential revenue improvement in both Life Science and Clinical Diagnostics
- Process chromatography to decline sequentially and YoY, offset by strength in DDPCR and quality controls
For full-year 2025, management maintained guidance:
- Currency-neutral revenue growth flat to 1%
- Non-GAAP gross margin 53.5% to 54.5%, operating margin 12% to 13%
Management highlighted:
- No expectation of a U.S. research budget flush in Q4, with continued cautious customer spending
- Annualization of China reimbursement headwind in diagnostics, with macro risks persisting into 2026
Takeaways
Bio-Rad’s Q3 execution demonstrates resilience in a volatile demand environment, with process chromatography offsetting research funding headwinds and cost actions supporting margin. The company’s innovation pipeline and operational initiatives provide a path to margin expansion in 2026, but macro and funding risks remain elevated.
- Process Chromatography Was a Temporary Tailwind: Q3 order timing drove growth, but normalization is expected, making sustained outperformance unlikely without broader funding recovery.
- Margin Expansion Hinges on Execution: Lean operations and supply chain leverage are critical as end-market growth remains muted.
- 2026 Will Test Recovery Narrative: Investors should watch for signs of U.S. research funding thaw, China macro stabilization, and DDPCR platform conversion to revenue.
Conclusion
Bio-Rad delivered stable results in Q3 2025, leveraging process chromatography strength and disciplined cost control to offset persistent research and China headwinds. The company remains focused on operational efficiency and innovation, but investors should be attentive to funding and macro risks as the company enters a critical period for margin and top-line recovery.
Industry Read-Through
Bio-Rad’s quarter reflects broader industry themes: U.S. academic and biotech funding caution is pressuring instrument demand across the life science tools sector, while order timing in bioprocessing continues to create revenue volatility for suppliers. China’s reimbursement and macro uncertainties remain a key risk for diagnostics peers, with quality controls and diversified portfolios offering some insulation. Margin expansion is increasingly reliant on operational discipline rather than volume growth, a trend likely to persist industry-wide into 2026. Investors should expect continued cautious outlooks and focus on execution and innovation pipelines across the diagnostics and research tools landscape.